The founder, President and the CEO of Seattle Genetics Clay Siegall, has been appointed as an outside director in one of the largest biotechnology company, Mirna Therapeutics that specializes in developing and commercializing MicroRNA therapeutics.
According to the Chief Executive Officer of Mirna Therapeutics Paul Lammers, everyone at the company is excited about having Siegall as part of their distinguished board of directors. Siegall has more than enough experience in the pharmaceutical industry. His success in building an oncology company will be invaluable to Mirna’s team and will guide the company to its advancement in the development of MicroRNA-based therapeutics.
Micro-RNA therapeutics is an extensive cancer research field that’s expected to position the company as a strong pipeline of product candidates. Given the company’s early involvement in miRNA field, the arrival of Siegall will propel the working of the team to advance its favorable programs for patients already in needs.
Clay Siegall established Seattle Genetics immediately after graduating from the George Washington University and the University of Maryland, where he studied Genetics and Zoology respectively in 1998. Under his leadership, the company created a diverse pipeline of antibody-based therapies that addressed immediate medical needs of cancer patients. Seattle Genetics launched its first commercial product designated ADCETRIS in 2011.
After operating for a few years, the company engaged in a few strategic partnerships with several pharmaceutical and biotechnology companies on oncology. Among these companies include Bayer and Progenics, Genentech, CuraGen, and Medlmmune. The company raised capital through private and public financings and in 2012, Clay Siegall secured over $675 million, including its initial public offering in 2012.
Apart from Seattle Genetics, Clay Siegall has founded a couple of other research institutes including National Cancer Institute, Bristol-Myers Squibb Pharmaceutical Research Institute and the National Institute of Health between 1991 and 1998.
Presently, he is a member of the board of directors at Washington Biotechnology and Biomedical Association, the Chairman of the Alder BioPharmaceuticals, and a member of the board of governors of the Fred Hutchinson Cancer Research Institute.